Edition:
United States

Orexo AB (ORX.ST)

ORX.ST on Stockholm Stock Exchange

37.30SEK
25 Sep 2017
Change (% chg)

-- (--)
Prev Close
37.30kr
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
99,986
52-wk High
53.75kr
52-wk Low
26.00kr

Chart for

About

Orexo AB is a Sweden-based company active within the pharmaceutical industry. It focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. The Company has four commercialized products, several projects... (more)

Overall

Beta: 1.74
Market Cap(Mil.): kr1,288.33
Shares Outstanding(Mil.): 34.54
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 30.87 15.95
EPS (TTM): -- -- --
ROI: -- 14.31 15.19
ROE: -- 15.61 13.87

BRIEF-Orexo says EMA issues positive opinion for opioid dependence treatment with Zubsolv

* CHMP positive opinion for opioid dependence treatment with Zubsolv® (buprenorphine and naloxone) in Europe

Sep 15 2017

BRIEF-Orexo AB Q2 revenue SEK 159.1 million

* Orexo interim report q2 2017 Source text for Eikon: Further company coverage:

Jul 11 2017

BRIEF-Orexo Q2 net revenues falls to SEK 159.1 million

* REUTERS POLL: OREXO Q2 REVENUES WERE SEEN AT 148 MILLION SEK, EBIT -4.2 MILLION SEK Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Jul 11 2017

BRIEF-Orexo receives USD 2.5 mln milestone payment from AstraZeneca

* Orexo receives USD 2.5 million milestone payment from AstraZeneca as OX-CLI advances into clinical trials Source text for Eikon: Further company coverage:

Jun 02 2017

BRIEF-Orexo Q1 operating loss narrows

* Says guidance issued in connection with full year report 2016 confirmed Source text for Eikon: Further company coverage: (Stockholm Newsroom)

Apr 20 2017

Earnings vs. Estimates